Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Using Low Dose Subcutaneous IL-2, Vinblastine and GM-CSF in the Treatment of Metastatic Renal Cell Carcinoma

NCT00003181 is registered in ClinicalTrials.gov with Hope Cancer Institute, Inc. as lead sponsor.

NCT NCT00003181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Using Low Dose Subcutaneous IL-2, Vinblastine and GM-CSF in the Treatment of Metastatic Renal Cell Carcinoma
Lead sponsor
Hope Cancer Institute, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 1997
Completion date
Not reported
Enrollment
35 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

kidney cancer